Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nutriband Inc. Warrant (NTRBW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NTRBW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.49% | Avg. Invested days 45 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 7755 | Beta 0.32 | 52 Weeks Range 0.35 - 5.25 | Updated Date 02/24/2025 |
52 Weeks Range 0.35 - 5.25 | Updated Date 02/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -220.94% |
Management Effectiveness
Return on Assets (TTM) -35.79% | Return on Equity (TTM) -80.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5108179 |
Shares Outstanding - | Shares Floating 5108179 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nutriband Inc. Warrant
Company Overview
History and Background
Nutriband Inc. is a pharmaceutical company focused on developing transdermal drug delivery products. Its origin stems from creating abuse-deterrent fentanyl patches. The warrant allows the holder to purchase shares of Nutriband's common stock under specific terms and conditions.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of transdermal drug delivery systems.
- Abuse-Deterrent Technology: Specializes in creating tamper-resistant drug delivery solutions, particularly for opioids.
Leadership and Structure
Details on Nutriband's specific leadership team and organizational structure would require specific company filings. Generally, this would include a CEO, CFO, board of directors, and various department heads.
Top Products and Market Share
Key Offerings
- AvertRx: Abuse-deterrent transdermal technology. Aims to address the opioid crisis by providing a safer way to deliver medications. Market share data is not readily available; competitors in abuse-deterrent technologies include companies like Purdue Pharma (although facing legal challenges) and Teva Pharmaceutical Industries (TEVA).
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly transdermal drug delivery, is driven by innovation, regulatory approvals, and patient needs. Abuse-deterrent technologies are in high demand due to the opioid crisis.
Positioning
Nutriband is positioning itself as an innovator in abuse-deterrent transdermal technology, targeting a niche market within the pharmaceutical sector. Its competitive advantage lies in its proprietary technology.
Total Addressable Market (TAM)
The TAM for abuse-deterrent opioid formulations is estimated in the billions of dollars. Nutriband's positioning depends on the success of its AvertRx technology and its ability to capture a significant share of the market.
Upturn SWOT Analysis
Strengths
- Proprietary abuse-deterrent technology
- Focus on a high-demand market (opioid crisis)
- Potential for strategic partnerships
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Competition from larger pharmaceutical companies
Opportunities
- Expanding product pipeline
- Strategic alliances with pharmaceutical companies
- Government funding for abuse-deterrent technologies
Threats
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Patent infringement litigation
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- TEVA
- ENDP
- PRGO
- CRL
Competitive Landscape
Nutriband faces significant competition from larger, established pharmaceutical companies with greater resources and broader product portfolios. Its competitive advantage lies in its specialized abuse-deterrent technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth would depend on the success of AvertRx and other product candidates.
Future Projections: Future projections require analyst estimates based on market trends, regulatory approvals, and product pipeline progress.
Recent Initiatives: Recent strategic initiatives include securing patents and pursuing regulatory approvals for AvertRx.
Summary
Nutriband is a small pharmaceutical company focused on abuse-deterrent transdermal technology. It has potential in a high-demand market, but faces challenges from larger competitors and regulatory hurdles. Its success depends on securing approvals for AvertRx and expanding its product pipeline. The warrants derive their value solely from the performance of the underlying Nutriband stock. Funding is a constant concern for them to continue operation and development
Similar Companies
- TEVA
- ENDP
- PRGO
- CRL
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nutriband Inc. Warrant
Exchange NASDAQ | Headquaters Orlando, FL, United States | ||
IPO Launch date 2021-10-01 | Founder, CEO & Director Mr. Gareth Sheridan | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nutriband.com |
Full time employees - | Website https://www.nutriband.com | ||
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.